Disc Medicine said patient demand for its bitopertin program in erythropoietic protoporphyria remains strong after enrolling 183 patients in the APOLLO confirmatory study, above the original target of 150. The enrollment overage suggests solid clinical interest and support for the program. The news is positive for execution but likely modest in immediate market impact.
Disc Medicine said patient demand for its bitopertin program in erythropoietic protoporphyria remains strong after enrolling 183 patients in the APOLLO confirmatory study, above the original target of 150. The enrollment overage suggests solid clinical interest and support for the program. The news is positive for execution but likely modest in immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
